Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
Sponsor: ViiV Healthcare
Summary
VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studies of VH4770359 in people living with HIV.
Official title: A Multi-part, Phase 1, First-Time-in-Human Study to Investigate Safety, Tolerability, and PK of VH4770359 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
214
Start Date
2026-05-14
Completion Date
2027-05-05
Last Updated
2026-07-13
Healthy Volunteers
Yes
Conditions
Interventions
VH4770359
Participants will receive the assigned dose formulation of VH4770359 orally.
Placebo
Participants will receive placebo to match the VH4770359 dose formulation.
Midazolam
Participants receive 2 mg Midazolam on Days -1, Day 1 and Day 14.
Locations (1)
GSK Investigational Site
Baltimore, Maryland, United States